Dhaity-Dhaity G, Núñez-Zárate P, Mejía-López MD, Melo-Guzmán G, Dhaity-Nuñez G, Dhaity-Nuñez JP

Language: Spanish
References: 25
Page: 136-142
PDF size: 229.53 Kb.

ABSTRACT

Introduction: Acute lymphoblastic leukemia (ALL), is a type of cancer that affects the multipotent cells of the blood and according to the clinical picture varies from acute to chronic. Most cases occur in children to whom aggressive treatments should be applied, which can cause systemic problems because most of the drugs used have a long half-life, in addition to being substances that affect all cells that are frequently changing or regeneration, so that organs such as liver and kidney can be compromised resulting in additional diseases or clinical conditions that further harm the health of patients. Objective: The present study aimed to elucidate the efficacy of high-dose treatment of methotrexate (Mtr) and its combination with cytosine arabinoside (ArC), as well as the half-life of the drug in children with ALL. Results: The results obtained do not provide evidence that there is a difference between the application of Mtx either as a single treatment or in combination with ArC and the half-life in both treatments appears to be the same. Conclusion: The treatment of Mtx and its combination with ArC have the same effect in the treatment of acute lymphoblastic leukemia, so any of these treatments will cause the same unwanted toxic effects in patients, as the half-life and adverse effects of the drug are the same.

REFERENCES

1. Mejía-Aranguré JM, Fajardo-Gutiérrez A, Bernáldez-Ríos R, Farfán-Canto JM, Ortíz-Fernández A, et al. Incidence trends of acute leukemia among the children of Mexico City: 1982-1991. Arch Med Res 2006; 27(2): 223-7.

2. Bleyer WA, Coccia PF, Sather HN, Level C, Lukens J, Niebrugge DJ, et al. Reduction in central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexante dosage regimen. J Clin Oncol 1983; 1(5): 317-25.

3. Schlieben S, Borkhardt A, Reinisch I, Ritterbach J, Janssen JW, Ratei R, et al. Incidence and clinical outcome of children with BCR/ABL positive acute lymphoblastic leukemia therapy trials ALL-13 BM-90 and Co ALL-05-92. Leukemia. 1996; 10(6): 957-63.

4. Freeman AI, Weinberg V, Brecher ML, Jones B, Glicksman AS, Sinks LF, et al. Comparison of intermediate-dose metotrexate with cranial irradiation for the post-induction treatment of acute lymphocytic leukemia in children. N Engl J Med 1983; 308(9): 477-84.

5. Pinkel D, Woo S. Prevention and treatment of meningeal leukemia in children. Blood 2004; 84(2): 355-66.

6. Cadman ED, Eiferman F. Mechanism of synergistic cell killing when methotrexate precedes cytosine arabinoside: study of L1210 and human leukemic cells. J Clin Invest 1979; 64(3): 788-97.

7. Rivera GK. Advances in therapy for childhood non-b lymphoblastic leukemia. Bailliere’s Clin Haematol 1994; 7(2): 273-98.

8. Ochs JJ. Neurotoxicity due to central nervous system therapy for childhood leukemia. Am J Pediatr Hematol Oncol 1989; 11(1): 93-105.

9. Pui CH, Howard SC. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol 2008; 9(3): 257-68.

10. Niemeyer CM, Gelber RD, Tarbell NJ, Donnelly M, Clavell LA, Blattner SR, et al. Low-doses versus high-dose metotrexate during remission induction in childhood acute lymphoblastic leukemia (Protocol 81-01 update). Blood 1991; 78(10): 2514-9.

11. Silverman LB, McLean TW, Gelber RD, Donnelly MJ, Gilliland DG, Tarbell NJ, et al. Intensified therapy for infants with acute lymphoblastic leukemia results of Dana-Farber Cancer Institute Consortium. Cancer 1997; 80(12): 2285-95.

12. García HI, Rey GC, Concha TA, Arcos SM, Mayordomo CJ. Neurotoxicidad subaguda letal por metotrexato intratecal. Bol Pediatr 2012; 52: 37-42.

13. De Braganca KC, Packer RJ. Neurotoxicity of chemotherapeutic and biologic agents in children with cancer. Curr Neurol Neurosci Rep 2008; 8(2): 114-22.

14. Shuper A, Stark B, Kornreich L, Cohen IJ, Aviner S, Steinmetz A, et al. Methotrexate treatment protocols and the central nervous system: significant cure with significant neurotoxicity. J Child Neurol 2000; 15(9): 573-80.

15. Momparler RL. A model for the chemotherapy of acute leukemia with 1-β-D arabinofuranocytosine. Cancer Res 1974; 34: 1775-87.

16. Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Eng J Med 1977; 297(12): 630-4.

17. Krance RA, Newman EM, Ravinadrath, Harris MB, Brecher M, Wimmer R, et al. A pilot study of intermediate-dose methotrexate and cytosine arabinoside, “spread-out” or “up-front”, in continuation therapy for childhood non-T, non-B acute lymphoblastic leukemia. A Pediatric Oncology Group study. Cancer 1991; 67(3): 550-6.

18. Lippens RJ. Metotrexate. Pharmacology and pharmacokinetics. Am J Pediatr Hematol Oncol 1984; 6(4): 379-95.

19. Lippens RJJ. Methotrexante use in pediatr chemotherapy. Am J Pediatr Hematol Oncol 1994; 6(4): 397-413.

20. Evans WE, Crom WR, Abromowitch M, Dodge R, Look AT, Bowman WP, et al. Clinical Pharmacodynamics of high-dose metotrexate in acute lymphocytic leukemia. N Engl J Med 1986; 314(8): 417-77.

21. Taketomo CK, Hurlburt HJ, Kraus DM. Pediatric dosage handbook. Lexi-Comp, USA, 2000.

22. Herzig RH, Herzig GP, Wolff SN, Hines JD, Fay JW, Phillips GL. Central nervous system effects of high dose cytosine arabinoside. Semin Oncol 1987; 14(2 Suppl 1): 21-4.

23. Frei E 3rd, Bickers JN, Hewlett JS, Lane M, Leary WV, Talley RW. Dose schedule and anti tumor studies of arabinosyl cytosne. Cancer Res 1969; 29(7): 1325-32.

24. Buchholz B, Free E, Eisenbarth, et al. Time course of methotrexante polyglutamate formation and degredation in the pre b leukemia cell line malm & in lymphoblast from children with leukemia. Eur J Cancer 2006; 32(12): 2101-7.

25. Lares-Asseff I, Paredes R, Taboada C, Cravioto J, Velázquez M, Roldán RM y cols. Farmacocinética del metotrexato en niños con leucemia aguda linfoblástica. Bol Med Hosp Infant Mex 1988; 45(10): 671-80.